Form 13-F position report

ALDEYRA THERAPEUTICS INC

Reported by PERCEPTIVE ADVISORS LLC

ALDX CUSIP 01438T106 Manager CIK 0001224962

Reported 11,350,085 shares, unchanged from the prior quarter.

Reported value 30.3%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 2.22% This manager · Q4 2022
Shares 11,350,085 Quarter-end amount reported
Reported value $78,996,592 Fair value at quarter end
Consecutive quarters held 32 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 86956000
2021-12-31 39616000
2022-03-31 44023000
2022-06-30 39516000
2022-09-30 60609000
2022-12-31 78996592
2023-03-31 112706344
2023-06-30 95227213
2023-09-30 75818568
2023-12-31 30163487
2024-03-31 28101026
2024-06-30 30703067
2024-09-30 49996837
2024-12-31 46286496
2025-03-31 53336143
2025-06-30 15517747
2025-09-30 27260463
2025-12-31 21681574
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for ALDEYRA THERAPEUTICS INC held by PERCEPTIVE ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -4,185,632 (-100.0%) 0 $0 2026-05-15
Q4 2025 Reduced 4,185,632 -1,036,679 (-19.9%) 0.39% $21,681,574 2026-02-17
Q3 2025 Added 5,222,311 +1,170,680 (28.9%) 0.79% $27,260,463 2025-11-14
Q2 2025 Reduced 4,051,631 -5,224,220 (-56.3%) 0.58% $15,517,747 2025-08-14
Q1 2025 Unchanged 9,275,851 0 (0.0%) 1.88% $53,336,143 2025-05-15
Q4 2024 Unchanged 9,275,851 0 (0.0%) 1.28% $46,286,496 2025-02-14
Q3 2024 Unchanged 9,275,851 0 (0.0%) 1.06% $49,996,837 2024-11-14
Q2 2024 Added 9,275,851 +682,265 (7.9%) 0.74% $30,703,067 2024-08-14
Q1 2024 Unchanged 8,593,586 0 (0.0%) 0.49% $28,101,026 2024-05-15
Q4 2023 Reduced 8,593,586 -2,756,499 (-24.3%) 0.67% $30,163,487 2024-02-14
Q3 2023 Unchanged 11,350,085 0 (0.0%) 2.53% $75,818,568 2023-11-14
Q2 2023 Unchanged 11,350,085 0 (0.0%) 2.76% $95,227,213 2023-08-14
Q1 2023 Unchanged 11,350,085 0 (0.0%) 3.33% $112,706,344 2023-05-15
Q4 2022 Unchanged 11,350,085 0 (0.0%) 2.22% $78,996,592 2023-02-14
Q3 2022 Added 11,350,085 +1,446,206 (14.6%) 1.76% $60,609,000 2022-11-14
Q2 2022 Unchanged 9,903,879 0 (0.0%) 1.24% $39,516,000 2022-08-15
Q1 2022 Unchanged 9,903,879 0 (0.0%) 0.88% $44,023,000 2022-05-16
Q4 2021 Unchanged 9,903,879 0 (0.0%) 0.61% $39,616,000 2022-02-14
Q3 2021 Unchanged 9,903,879 0 (0.0%) 1.26% $86,956,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

108 managers reported ALDEYRA THERAPEUTICS INC for Q4 2022.

Managers reporting ALDEYRA THERAPEUTICS INC in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PERCEPTIVE ADVISORS LLC This report Unchanged 11,350,085 0 2.22% $78,996,592 32 qtrs
VANGUARD GROUP INC Reduced 2,492,269 -23,615 < 0.01% $17,346,193 31 qtrs
Knoll Capital Management LLC Added 1,948,090 +70,785 30.6% $13,558,706 32 qtrs
EAGLE ASSET MANAGEMENT INC Added 1,771,689 +313,681 0.08% $12,330,000 7 qtrs
Verition Fund Management LLC Reduced 1,558,322 -843,917 0.17% $10,845,921 11 qtrs
BlackRock Inc Added 972,436 +2,350 < 0.01% $6,768,154 24 qtrs
FMR LLC Reduced 966,076 -84,383 < 0.01% $6,723,889 35 qtrs
Laurion Capital Management LP Unchanged 956,900 0 0.03% $6,660,024 3 qtrs
DIMENSIONAL FUND ADVISORS LP Added 890,232 +210,219 < 0.01% $6,196,000 21 qtrs
Prosight Management LP Reduced 858,709 -352,091 3.26% $5,976,615 17 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
11,350,085
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.